Treatment for age-related macular degeneration that has not improved with standard therapy
Part of Eyes & vision clinical trials.
This trial tests a new treatment for people with a specific type of age-related macular degeneration (AMD) that has not improved after standard anti-VEGF injections. The goal is to see if it can stop vision loss and reduce retinal damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have neovascular (wet) age-related macular degeneration in at least one eye.
- Your vision in the study eye is between 20 and 70 letters on an eye chart (roughly 20/200 to 20/40).
- You have certain retinal changes, like a tear in the pigment layer, atrophy, thinning of the choroid, or fluid that hasn't gone away with standard treatment.
- You have had at least two anti-VEGF injections (like Eylea or Lucentis) in the past year, but your vision or fluid has not improved or has worsened.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a specific eye surgery plus targeted clot-busting medicine and gas can improve vision after bleeding under the retina from “wet” age-related macular degeneration. It aims to reduce how long the bleeding lasts and help protect the central vision.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a new CRISPR-based treatment for wet age-related macular degeneration (AMD). It aims to stop vision loss by targeting the cause of abnormal blood vessel growth in the eye. This study is for people who have already tried anti-VEGF injections but might not be responding well enough.
This trial tests a new treatment called IVB103 for people with wet age-related macular degeneration (AMD). It aims to see if the injection is safe and effective for those who have already had anti-VEGF therapy. You may qualify if you have active disease and have had at least two prior anti-VEGF treatments.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
Hear when a new Neovascular Age-related Macular Degeneration (AMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.